Adding Lenvatinib to Pembrolizumab Does Not Provide Additional Benefit in Patients with Unresectable Advanced Melanoma By Ogkologos - September 10, 2025 294 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the LEAP-003 study Source RELATED ARTICLESMORE FROM AUTHOR Nivolumab Added to Cisplatin and Radiotherapy Improves DFS in Patients with High-Risk Resected Locally Advanced SCCHN EMA Recommends Granting a Marketing Authorisation for Aumolertinib FDA Approves Niraparib and Abiraterone Acetate Plus Prednisone for BRCA2-mutated Metastatic Castration-Sensitive Prostate Cancer MOST POPULAR Leading Change in Cancer Clinical Research, Because Our Patients Can’t Wait May 31, 2024 Cómo aprendí a sobrellevar la culpa del superviviente después del cáncer May 4, 2022 We want every scientist to thrive in cancer research July 28, 2023 New Treatments for Non-Small Cell Lung Cancer With an EGFR Mutation:... December 16, 2021 Load more HOT NEWS Immunotherapy and… Nothing Else? Studies Test Potential Paradigm Shift in Cancer... Newly Developed RSClin Provides Prognostic Information in HR-positive, HER2-negative Early Breast... ΚΑΡΚΙΝΟΣ ΧΟΛΗΔΟΧΟΥ ΚΥΣΤΕΩΣ How I Took Charge of My Cancer Care and Found a...
